Beginning January 1, 2025, Humira (brand) will be removed from BlueCross BlueShield of South Carolina and BlueChoice HealthPlan’s Lowest Net Cost, Exchange and Premium formularies. Adalimumab biosimilars will instead be the preferred products for each of these formularies. Humira biosimilars are designed to be biologically similar to the reference medication and are just as safe and effective.

This new biosimilar strategy provides continued quality of care for patients, guaranteed supply, availability of high-concentration doses, and affordability for patients, including manufacturer copay assistance programs and significant cost reduction for plan sponsors.

*Low list price option

Do you NEED HELP finding a plan that covers your HUMIRA prescription? CLICK HERE